Genocea Biosciences News Releases https://ir.genocea.com/ Genocea Biosciences News Releases en Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products https://ir.genocea.com/news-releases/news-release-details/genocea-announces-research-collaboration-iovance-explore CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research collaboration with Iovance Biotherapeutics, Inc. to assess the potential of applying Genocea’s Thu, 16 May 2019 13:00:00 -0400 Genocea Biosciences News Releases 10506 Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial https://ir.genocea.com/news-releases/news-release-details/genocea-announces-positive-interim-immunogenicity-data-gen-009 Post-vaccination immune responses detected to 93% of vaccine neoantigens  in first three patients analyzed Additional data to be presented June 1 st at ASCO 2019 and discussed on a conference call and webcast on June 3 rd CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc Thu, 16 May 2019 08:00:00 -0400 Genocea Biosciences News Releases 10496 Genocea Provides Corporate Update, Including First-Quarter 2019 Financial Results https://ir.genocea.com/news-releases/news-release-details/genocea-provides-corporate-update-including-first-quarter-2019 Company anticipates presenting first GEN-009 immunogenicity data at ASCO 2019 Conference call today at 9:00 am ET CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today Tue, 30 Apr 2019 08:00:00 -0400 Genocea Biosciences News Releases 10456 Genocea to Host Quarterly Corporate Update Conference Call & Webcast on April 30th at 9:00 am ET https://ir.genocea.com/news-releases/news-release-details/genocea-host-quarterly-corporate-update-conference-call-0 CAMBRIDGE, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its first-quarter 2019 financial results and corporate update conference call and live audio webcast on Tuesday, Tue, 23 Apr 2019 08:00:00 -0400 Genocea Biosciences News Releases 10446 Genocea to Present at 18th Annual Needham Healthcare Conference https://ir.genocea.com/news-releases/news-release-details/genocea-present-18th-annual-needham-healthcare-conference CAMBRIDGE, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the 18 th Annual Wed, 03 Apr 2019 16:01:00 -0400 Genocea Biosciences News Releases 10431 Genocea Presents Data at AACR 2019 Supporting Utility of ATLAS™ Platform in Predicting Melanoma Patient Response to Immune Checkpoint Inhibitors https://ir.genocea.com/news-releases/news-release-details/genocea-presents-data-aacr-2019-supporting-utility-atlastm CAMBRIDGE, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the presentation of data from ATLAS™, its ex vivo platform for comprehensively profiling patients’ Tue, 02 Apr 2019 13:00:00 -0400 Genocea Biosciences News Releases 10426 Genocea to Present at the Cowen & Company 39th Annual Health Care Conference https://ir.genocea.com/news-releases/news-release-details/genocea-present-cowen-company-39th-annual-health-care-conference CAMBRIDGE, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the Cowen & Wed, 06 Mar 2019 08:05:00 -0500 Genocea Biosciences News Releases 10366 Genocea Reports Fourth Quarter 2018 Results and Announces Hiring of New Chief Financial Officer https://ir.genocea.com/news-releases/news-release-details/genocea-reports-fourth-quarter-2018-results-and-announces-hiring Company advancing lead clinical-stage neoantigen cancer vaccine candidate and expanding pipeline into adoptive cell therapy Diantha Duvall to join as CFO, bringing broad life science financial leadership experience Conference call today at 9:00 am ET CAMBRIDGE, Mass. , Feb. Thu, 28 Feb 2019 08:00:00 -0500 Genocea Biosciences News Releases 10341 Genocea to Host Quarterly Corporate Update Conference Call & Webcast on February 28 at 9:00 am ET https://ir.genocea.com/news-releases/news-release-details/genocea-host-quarterly-corporate-update-conference-call-webcast CAMBRIDGE, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 28 at 9:00 am ET to provide a Thu, 21 Feb 2019 08:00:00 -0500 Genocea Biosciences News Releases 10316 Genocea Announces Private Placement Financing of Up to $39 Million https://ir.genocea.com/news-releases/news-release-details/genocea-announces-private-placement-financing-39-million CAMBRIDGE, Mass. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement with certain existing and new investors providing for the purchase Tue, 12 Feb 2019 08:30:00 -0500 Genocea Biosciences News Releases 10236